FASENRA▼ benralizumab

FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.1

Mode of action

Fasenra directly binds to IL-5Rα, preventing IL-5 from binding to eosinophils2 .By recruiting natural killers cells via IL-5R⍺, FASENRA actively targets and depletes eosinophils2. FASENRA promotes eosinophil apoptosis without degranulation or the release of eosinophil mediators3.

FASENRA Mode of Action Image
FASENRA Mode of Action Image

 

FASENRA is the only severe asthma biologic that provides rapid, near-complete depletion of blood eosinophils in 24 hours1, 2 ,4